Stocktoria

Cytek Biosciences, Inc. CTKB

Nasdaq · stock · Laboratory Analytical Instruments · website · IPO 2021-07-23 · LEI

Cytek Biosciences, Inc. financials (annual)

Revenue
$92.8M $128.0M $164.0M $193.0M $200.5M $201.5M 202020212022202320242025
Net income
$19.4M $3.0M $2.5M -$12.1M -$6.0M -$66.5M 202020212022202320242025
Free cash flow
$13.6M $266000 -$22.0M $633000 $21.9M -$8.8M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue$201.5M$200.5M$193.0M$164.0M$128.0M$92.8M
Gross profit$104.5M$111.1M$109.4M$101.0M$79.1M$51.7M
R&D expense$36.5M$39.4M$44.2M$34.9M$24.4M$13.7M
Operating income-$40.4M-$20.5M-$27.8M-$1.8M$9.2M$13.7M
Interest expense——$2.1M$2.6M$1.7M$333,000
Income tax$36.7M$320,000-$3.6M-$1.2M$2.9M-$5.0M
Net income-$66.5M-$6.0M-$12.1M$2.5M$3.0M$19.4M
EPS (diluted)——$-0.09$0.02$0.00$0.10
Operating cash flow-$4.7M$25.4M$5.3M-$12.2M$4.6M$15.2M
Free cash flow-$8.8M$21.9M$633,000-$22.0M$266,000$13.6M
Cash & equivalents$90.9M$98.7M$167.3M$296.6M$364.6M$165.2M
Inventory$48.4M$43.9M$60.9M$48.2M$32.2M$23.0M
Total assets$461.5M$499.5M$494.5M$519.5M$463.3M$220.0M
Total liabilities$119.8M$103.8M$101.4M$93.9M$57.9M$41.7M
Shareholders' equity$341.7M$395.7M$393.1M$425.5M$405.4M-$16.0M

Growth · year-over-year · Revenue CAGR 16.8%

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue growth+0.5%+3.9%+17.7%+28.2%+37.8%—
Net income growth——-589.0%-17.9%-84.4%—
EPS growth——-550.0%—-100.0%—
Free cash flow growth-140.1%+3352.4%—-8362.8%-98.0%—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.